MindMed notes MM120 Phase 2b GAD data in JAMA

Mind Medicine (MindMed) Inc. filed a report stating that it has issued a press release about new clinical data.

Rhea-AI Filing Summary

Mind Medicine (MindMed) Inc. filed a report stating that it has issued a press release about new clinical data. On September 4, 2025, the company announced the publication of results from its Phase 2b clinical trial of MM120 (Lysergide D-Tartrate) for Generalized Anxiety Disorder in the Journal of the American Medical Association. The related press release is included as an exhibit to provide more detail on the trial results and their context.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mind Medicine (MNMD) disclose in this 8-K filing?

Mind Medicine (MindMed) Inc. disclosed that it issued a press release announcing the publication of results from its Phase 2b clinical trial of MM120 in Generalized Anxiety Disorder in the Journal of the American Medical Association.

What is MM120 in Mind Medicine's recent 8-K filing for MNMD?

MM120 is described as Lysergide D-Tartrate, a compound Mind Medicine is studying in a Phase 2b clinical trial for Generalized Anxiety Disorder.

Where were Mind Medicine's MM120 Phase 2b trial results published?

The results from Mind Medicine's Phase 2b clinical trial of MM120 for Generalized Anxiety Disorder were published in the Journal of the American Medical Association.

What exhibit is included with Mind Medicine's MNMD 8-K related to MM120?

The filing includes Exhibit 99.1, which is a press release dated September 4, 2025, discussing the publication of the MM120 Phase 2b trial results.

Does the Mind Medicine 8-K describe the MM120 trial outcomes in detail?

The 8-K notes that the Phase 2b trial results of MM120 in Generalized Anxiety Disorder were published and refers readers to the attached press release for further information.

Who signed Mind Medicine's September 4, 2025 8-K filing?

The 8-K was signed on behalf of Mind Medicine (MindMed) Inc. by Robert Barrow, the company's Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 11:15 AM EDT Learn about SEC filing dates

false000181381400018138142025-09-042025-09-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 04, 2025

Mind Medicine (MindMed) Inc.

(Exact name of Registrant as Specified in Its Charter)

British Columbia			001-40360	98-1582438
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
One World Trade Center Suite 8500
New York, New York				10007
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (212) 220-6633

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		MNMD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 4, 2025, Mind Medicine (MindMed), Inc. (the “Company”) issued a press release (the “Press Release”) announcing the publication of the results from the Company's Phase 2b clinical trial of MM120 (Lysergide D-Tartrate) in Generalized Anxiety Disorder in the Journal of the American Medical Association. A copy of the Press Release is attached as Exhibit 99.1 hereto, and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated September 4, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			MIND MEDICINE (MINDMED) INC.
Date:	September 4, 2025	By:	/s/ Robert Barrow
			Name: Robert Barrow Title: Chief Executive Officer